0001225208-18-010754.txt : 20180619
0001225208-18-010754.hdr.sgml : 20180619
20180619105521
ACCESSION NUMBER: 0001225208-18-010754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180618
FILED AS OF DATE: 20180619
DATE AS OF CHANGE: 20180619
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schechter Adam H
CENTRAL INDEX KEY: 0001376841
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 18906474
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
X0306
4
2018-06-18
0000310158
Merck & Co., Inc.
MRK
0001376841
Schechter Adam H
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH
NJ
07033
1
EVP & Pres-Global Human Health
Common Stock
2018-06-18
4
M
0
100000.0000
36.5600
A
100000.0000
D
Common Stock
2018-06-18
4
S
0
100000.0000
61.0016
D
0.0000
D
Common Stock
2018-06-18
4
S
0
34094.0000
61.0015
D
62765.9747
I
By Trust
Stock Option (right to buy)
36.5600
2018-06-18
4
M
0
100000.0000
0.0000
D
2012-05-04
2021-05-03
Common Stock
100000.0000
100000.0000
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5900 to $61.3200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.6100 to $61.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014.
Faye C. Brown as Attorney-in-Fact for Adam H. Schechter
2018-06-19